This effect was not restricted to Venetoclax, as knockout or pharmacologic inhibition of ABCC1 also sensitized AML cells to other BH3 mimetics, including ABT-737, Navitoclax and the novel BCL-2/BCL-xL inhibitor AZD-4320. The gene discussed is BCL2L1; the disease is acute myeloid leukemia.